RESUMEN
STUDY QUESTION: How common is the use of herbal supplements during pregnancy and does it adversely affect the pregnancy outcome? SUMMARY ANSWER: The use of herbal products during pregnancy is very common and daily almond oil spreading is associated with preterm birth (PTB). WHAT IS KNOWN AND WHAT THIS PAPER ADDS: Herbal drugs are often promoted as 'natural' and 'safe' and such claims attract pregnant women. More than a quarter of Italian pregnant women consume herbs every day for at least 3 months during pregnancy. We raise an alert over the habit of daily almond oil spreading since it seems to be associated with PTB. DESIGN: A multicenter retrospective cohort study performed over a 15-month period. PARTICIPANTS AND SETTING: Seven hundred women interviewed within 3 days of childbirth, in three public hospitals in northern Italy. MAIN RESULTS AND ROLE OF CHANCE: One hundred and eighty-nine women were considered 'regular users', since they consumed herbs every day, for at least 3 months. Almond oil, chamomile and fennel were the most commonly used herbs. Both length of gestation and birthweight were affected by herb consumption. Almond oil users showed more pre-term birth (29 of 189) than non-users (51 of 511). After adjusting for multiple pregnancies, smoking, advanced age and drug intake, almond oil users maintained an increased risk to give birth <37th week (odds ratio = 2.09, 95% confidence interval: 1.08-4.08). BIAS, CONFOUNDING AND OTHER REASONS FOR CAUTION: The association between daily spreading of almond oil and PTB only raises a hypothesis that requires confirmation in larger trials devoted to this topic. The relatively small sample size did not allow the investigation of other adverse pregnancy outcomes in herb users. GENERALIZABILITY TO OTHER POPULATIONS: The population under investigation did not significantly differ from the general population attending the same hospitals. STUDY FUNDING/COMPETING INTEREST(S): No conflict of interest exists. The study has been supported by a public grant from the University of Modena and Reggio Emilia. TRIAL REGISTRATION NUMBER: None.
Asunto(s)
Suplementos Dietéticos/efectos adversos , Preparaciones de Plantas/efectos adversos , Plantas Medicinales/química , Nacimiento Prematuro/etiología , Autocuidado , Administración Tópica , Adulto , Peso al Nacer , Manzanilla/efectos adversos , Manzanilla/química , Estudios de Cohortes , Suplementos Dietéticos/estadística & datos numéricos , Femenino , Foeniculum/efectos adversos , Foeniculum/química , Hospitales Públicos , Humanos , Italia/epidemiología , Aceites de Plantas/administración & dosificación , Aceites de Plantas/efectos adversos , Preparaciones de Plantas/administración & dosificación , Plantas Medicinales/efectos adversos , Embarazo , Nacimiento Prematuro/epidemiología , Estudios Retrospectivos , Riesgo , Factores de TiempoRESUMEN
Since the reports in Wuhan (China), in December 2019, of the first cluster of cases of pneumonia caused by the new Coronavirus called 2019-nCoV or SARS-CoV-2, there has been a pandemic spread of the infection. By now, we have no specific therapy to counteract this emergency. The latest epidemiological data suggest that children are just as likely as adults to get infected by the virus. Most of them show mild clinical pictures or are completely asymptomatic, but there is an increased risk for severe disease in infancy (<12 months of age) and in children with underlying medical conditions. In this article, research achievements on the treatment of pediatric SARS-CoV-2 infection are examined.
Asunto(s)
Antivirales/uso terapéutico , COVID-19/terapia , Factores Inmunológicos/uso terapéutico , Adenosina Monofosfato/análogos & derivados , Adenosina Monofosfato/uso terapéutico , Adolescente , Factores de Edad , Alanina/análogos & derivados , Alanina/uso terapéutico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Anticoagulantes/uso terapéutico , Portador Sano , Niño , Preescolar , Cloroquina/uso terapéutico , Terapia de Reemplazo Renal Continuo , Combinación de Medicamentos , Oxigenación por Membrana Extracorpórea , Glucocorticoides/uso terapéutico , Humanos , Hidroxicloroquina/uso terapéutico , Inmunización Pasiva , Inmunoglobulinas Intravenosas/uso terapéutico , Lactante , Recién Nacido , Interferón-alfa/uso terapéutico , Lopinavir/uso terapéutico , Oseltamivir/uso terapéutico , Receptores de Superficie Celular/uso terapéutico , Respiración Artificial , Ribavirina/uso terapéutico , Ritonavir/uso terapéutico , SARS-CoV-2 , Índice de Severidad de la Enfermedad , Trombosis/prevención & control , Tratamiento Farmacológico de COVID-19 , Sueroterapia para COVID-19RESUMEN
PURPOSE: To investigate changes in urinary PGE(2) after ibuprofen treatment in preterm infants with patent ductus arteriosus (PDA). METHODS: Twenty preterm infants with a hemodynamically significant PDA (gestational age, 28.6 +/- 2.3 weeks) and 20 controls (gestational age, 30.4 +/- 1.5 weeks) were prospectively enrolled at 48-72 h of life. After enrollment, the former underwent conventional ibuprofen-lysine treatment. At 48-72 h (T(0)) and 108-144 h of life (T(1)), urine samples were noninvasively collected in both groups to measure urinary PGE(2) concentrations (enzyme immunoassay method), and renal function was investigated. RESULTS: Urinary PGE(2) decreased significantly both in ibuprofen-treated patients (66.95 +/- 16.78 vs. 27.15 +/- 17.92 pg/mL, P < 0.001) and in controls (71.7 +/- 16.2 vs. 53.2 +/- 18.4 pg/mL, P < 0.001) from T(0) to T(1). However, urinary PGE(2) at T(1) was significantly lower (P < 0.001) in the ibuprofen group compared to the control group. Acute renal failure occurred in three ibuprofen-treated patients (15%). CONCLUSIONS: Ibuprofen markedly reduces (59.4%) urinary PGE(2) and may alter renal function in the newborn.
Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Dinoprostona/orina , Conducto Arterioso Permeable/tratamiento farmacológico , Ibuprofeno/uso terapéutico , Recien Nacido Prematuro , Lesión Renal Aguda/inducido químicamente , Antiinflamatorios no Esteroideos/efectos adversos , Creatinina/sangre , Femenino , Humanos , Ibuprofeno/efectos adversos , Recién Nacido , Infusiones Intravenosas , Masculino , Estudios ProspectivosRESUMEN
The incidence of infections is higher in the neonatal period than at any time of life. The basic treatment of infants with infection has not changed substantially over the last years. Antibiotics (with or without supportive care) are one of the most valuable resources in managing sick newborn babies. Early-onset (ascending or transplacental) or late-onset (hospital acquired) infections present different chronology, epidemiology, physiology and outcome. Some classes of antibiotics are frequently used in the neonatal period: penicillins, cephalosporins, aminoglycosides, glycopeptides, monobactams, carbapenems. Other classes of antibiotics (chloramphenicol, cotrimoxazole, macrolides, clindamycin, rifampicin and metronidazole) are rarely used. Due to emergence of resistant bacterial strains in Neonatal Intensive Care Units (NICU), other classes of antibiotics such as quinolones and linezolid will probably increase their therapeutic role in the future. Although new formulations have been developed for treatment of fungal infections in infants, amphotericin B remains first-line treatment for systemic Candida infection. Prophylactic antibiotic therapy is almost always undesirable. Challenges from pathogens and antibiotic resistance in the NICU may warrant modification of traditional antibiotic regimens. Knowledge of local flora and practical application of different antibiotic characteristics are key to an effective and safe utilization of antibiotics and antifungals in critical newborns admitted to the NICU, and especially in very low birth weight infants.
Asunto(s)
Antibacterianos/uso terapéutico , Antifúngicos/uso terapéutico , Unidades de Cuidado Intensivo Neonatal , Sepsis/tratamiento farmacológico , Profilaxis Antibiótica , Farmacorresistencia Microbiana , Humanos , Recién NacidoRESUMEN
Staphylococcus aureus remains one of the most common and troublesome microorganisms causing disease in humans, despite the development of effective antibiotics. Linezolid is a member of a new class of synthetic antibiotics called oxazolidinones, introduced into therapy due to the increasing resistance of Gram-positive pathogens to traditional antibiotics. Information about the pharmacokinetics and tolerability profile of linezolid in the pediatric population mostly derive from adult studies and especially in the neonatal field relatively few data are available. Here we summarize linezolid's characteristics and report data available in the literature regarding linezolid use in newborns and children. For this purpose, a Medline search was performed between 1990 and 2006 involving the term "linezolid" combined with the terms "newborn", "infant", "child", "pediatrics". Additional information was obtained from Reactions Weekly.
Asunto(s)
Acetamidas/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Oxazolidinonas/uso terapéutico , Acetamidas/efectos adversos , Antiinfecciosos/efectos adversos , Antiinfecciosos/uso terapéutico , Niño , Preescolar , Infección Hospitalaria/tratamiento farmacológico , Humanos , Lactante , Recién Nacido , Linezolid , Oxazolidinonas/efectos adversos , Resultado del TratamientoRESUMEN
AIMS: To determine in a case-control study possible associations between the development of acute renal failure in preterm newborns and therapeutic interventions, particularly drug treatments. METHODS: The study population was 172 preterm infants of <38 weeks gestation; 71 had acute renal failure and 101 were controls closely matched for gestational age and birth weight. Maternal and neonatal information was collected for both groups through questionnaires and interviews. Routine data on renal variables were also collected. Univariate and multivariate logistic regression analyses were performed. RESULTS: Very low birthweight infants were at high risk of acute renal failure (79% of cases were <1500 g). However, the acute renal failure was transient. Mothers of infants with acute renal failure received more drugs during pregnancy and delivery (mainly antibiotics and non-steroidal anti-inflammatory drugs). Of the possible therapeutic interventions, intubation, catheterisation, and phototherapy were mainly applied to case subjects. A low Apgar score and patent ductus arteriosus were diagnosed in a greater percentage of neonates with acute renal failure. Moreover, in the first few days of life and before diagnosis of acute renal failure, case subjects received more drugs (antibiotics, non-steroidal anti-inflammatory drugs, and diuretics) and for a longer time. In the multivariate logistic analysis, medullary hyperechogenicity (odds ratio (OR) 4.491; 95% confidence interval (CI) 1.879 to 10.731) and ceftazidime administration (OR 5.082; 95% CI 1.493 to 17.297) were associated with a greater risk of acute renal failure. CONCLUSIONS: The results suggest the need for careful monitoring of very low birthweight infants and attention to drug treatments, as it is difficult to differentiate between normality and renal failure in the first few days of life.
Asunto(s)
Lesión Renal Aguda/etiología , Enfermedades del Prematuro/etiología , Antibacterianos/efectos adversos , Antiinflamatorios no Esteroideos/efectos adversos , Puntaje de Apgar , Peso al Nacer , Estudios de Casos y Controles , Femenino , Edad Gestacional , Humanos , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro/terapia , Recién Nacido de muy Bajo Peso , Modelos Logísticos , Masculino , Intercambio Materno-Fetal , Embarazo , Efectos Tardíos de la Exposición Prenatal , Factores de RiesgoRESUMEN
When considering whether to administer drugs to women during pregnancy and lactation, we have to take into account that these substances may expose the fetus or neonate to multiple effects. This occurs because there is a unique situation where the maternal compartment is connected with the fetal or neonatal compartment through, respectively, the placental barrier or breast milk. The fetus in utero and the breast-fed neonate are to be considered as organisms exposed and sensitive to the effects of drugs that cross the placenta or enter the breast milk. This review focuses on the most frequently used antibiotics during pregnancy and lactation and presents useful suggestions for daily practice. Drugs that must be avoided are clearly underlined.
Asunto(s)
Anomalías Inducidas por Medicamentos/diagnóstico , Antibacterianos/uso terapéutico , Lactancia/efectos de los fármacos , Intercambio Materno-Fetal/efectos de los fármacos , Complicaciones del Embarazo/tratamiento farmacológico , Resultado del Embarazo , Anomalías Inducidas por Medicamentos/epidemiología , Adulto , Antibacterianos/efectos adversos , Antibacterianos/farmacocinética , Disponibilidad Biológica , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Estudios de Seguimiento , Edad Gestacional , Humanos , Recién Nacido , Edad Materna , Intercambio Materno-Fetal/fisiología , Dosis Máxima Tolerada , Embarazo , Efectos Tardíos de la Exposición Prenatal , Medición de RiesgoRESUMEN
A well-known nitric oxide (NO)-releasing compound, sodium nitroprusside (SNP), decreases in a dose-dependent manner NO synthase (NOS) activity induced in rat neutrophils by treatment with lipopolysaccharide (LPS). This inhibitory action of SNP seems not to be due to its direct effect on the enzyme activity. The strong nitrosonium ion (NO+) character of SNP could be responsible for its inhibition of NOS induction in neutrophils.
Asunto(s)
Aminoácido Oxidorreductasas/biosíntesis , Neutrófilos/efectos de los fármacos , Nitroprusiato/farmacología , Animales , Relación Dosis-Respuesta a Droga , Inducción Enzimática/efectos de los fármacos , Femenino , Lipopolisacáridos/farmacología , Neutrófilos/enzimología , Óxido Nítrico Sintasa , Ratas , Ratas Sprague-DawleyRESUMEN
Nitroflurbiprofen (NFP) causes significantly less gastric lesions than flurbiprofen (FP), probably because of its capacity to release nitric oxide (NO) in the stomach. Lipopolysaccharide (LPS), which induces the expression of an inducible type of NO synthase (iNOS) in rat stomach, also reduces gastric mucosal damage elicited by FP. Furthermore, both FP and NFP decrease significantly the amount of mRNA encoding iNOS induced by LPS in the stomach. The inhibitory effect of NFP seems to be due at least in part to its ability to release NO.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Flurbiprofeno/análogos & derivados , Flurbiprofeno/farmacología , Óxido Nítrico/metabolismo , Estómago/efectos de los fármacos , Animales , Femenino , Óxido Nítrico Sintasa/efectos de los fármacos , ARN Mensajero/biosíntesis , Ratas , Ratas Sprague-DawleyRESUMEN
The effects of a non-steroidal anti-inflammatory drug, flurbiprofen, and its nitro-derivative, nitroflurbiprofen, on inducible nitric oxide synthase in rat neutrophils were examined. Nitroflurbiprofen was shown to inhibit nitric oxide synthase induction caused by lipopolysaccharide administration, while flurbiprofen had no effect on nitric oxide synthase induction. This inhibitory action may be ascribed to nitric oxide released from nitroflurbiprofen.
Asunto(s)
Aminoácido Oxidorreductasas/biosíntesis , Antiinflamatorios no Esteroideos/farmacología , Flurbiprofeno/análogos & derivados , Flurbiprofeno/farmacología , Neutrófilos/efectos de los fármacos , Administración Oral , Análisis de Varianza , Animales , Separación Celular , Centrifugación por Gradiente de Densidad , Inducción Enzimática/efectos de los fármacos , Femenino , Lipopolisacáridos/toxicidad , Neutrófilos/enzimología , Nitratos/sangre , Óxido Nítrico Sintasa , Nitritos/sangre , Ratas , Ratas Sprague-DawleyRESUMEN
In this review we report data available from the literature on the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and the development of nephrotoxicity in the fetus, neonates and children. Up to the present day, several cases of severe and sometimes irreversible renal insufficiency have been described in neonates exposed to indomethacin prenatally or in the first days of life for treatment of patent ductus arteriosus (PDA). Until now, very few studies have been carried out on alternative treatments for PDA in preterm infants; ibuprofen has been shown to be as effective as indomethacin in closing the ductus in this patient group without affecting renal function. In children, NSAID-induced renal failure is a rare event and is usually reversible after discontinuation of the drug. However, caution should be taken when NSAIDs are administered to individuals with preexisting renal problems or with other potentially nephrotoxic drugs. In these situations, new approaches such as cyclo-oxygenase-2 selective inhibitors or prostanoid receptor selective antagonists could lead to alternative therapies for use in paediatrics.
Asunto(s)
Antiinflamatorios no Esteroideos/efectos adversos , Ibuprofeno/efectos adversos , Indometacina/efectos adversos , Prostaglandinas/metabolismo , Insuficiencia Renal/inducido químicamente , Antiinflamatorios no Esteroideos/uso terapéutico , Niño , Preescolar , Conducto Arterioso Permeable/tratamiento farmacológico , Femenino , Feto/efectos de los fármacos , Feto/metabolismo , Humanos , Ibuprofeno/uso terapéutico , Indometacina/uso terapéutico , Lactante , Recién Nacido , Embarazo , Efectos Tardíos de la Exposición Prenatal , Insuficiencia Renal/metabolismoRESUMEN
In this work PGE(2)concentrations were measured by a new EIA method in the urine of infants (mean age: 9.35+/-4.24 months) with recurrent urinary tract infections or renal malformations. Compared to healthy subjects, PGE(2)excretion rates resulted significantly higher in both pathological groups, in particular in subjects with obstructive uropathies (29.55+/-8.12 vs 18.37+/-4.64 pg/ml). We did not find any age- or pH-dependent difference in urinary excretion of PGE(2); none of the examined indices of renal function showed any significant relationship to PGE(2). These results suggest that this parameter, measured non-invasively in the urine, could help in the differential diagnosis between obstructive vs non-obstructive dilatation and in monitoring renal function in presence of recurrent UTI episodes.
Asunto(s)
Dinoprostona/orina , Técnicas para Inmunoenzimas/normas , Riñón/anomalías , Infecciones Urinarias/orina , Factores de Edad , Biomarcadores/orina , Estudios de Casos y Controles , Femenino , Humanos , Concentración de Iones de Hidrógeno , Técnicas para Inmunoenzimas/métodos , Lactante , Recién Nacido , Riñón/metabolismo , Modelos Lineales , Masculino , RecurrenciaRESUMEN
Urinary PGE(2) concentrations were assayed using a new EIA method, in 16 preterm and 18 term neonates at birth and 3 days later, since there is evidence that PGE(2) in urine are likely to reflect their renal generation and then could be correlated with kidney maturation or renal problems. PGE(2) concentrations were not different at birth (1.50+/-1.12 vs 1.56+/-1.94 ng/day), while resulted significantly higher in preterms, compared to terms, three days after birth (2.22+/-1.23 vs 1.39+/-0.79 ng/day). This increase in daily PGE(2) excretion observed only in preterm neonates could be due to an increased renal biosynthesis as a mechanism of compensatory response to prevent further decrements in renal plasma flow, since prostanoids play an important role in protecting the immature kidney from high levels of angiotensin II. Otherwise, the passive reabsorption of PGE(2) along the distal nephron could be altered because of kidney immaturity. The measurement of PGE(2) in urine of neonates, particularly prematures, could be useful to provide a better understanding of the homeostatic function of the kidney in the phase of adaptation to extra-uterine life.
Asunto(s)
Adaptación Fisiológica/fisiología , Dinoprostona/orina , Feto/metabolismo , Recién Nacido/orina , Riñón/fisiología , Envejecimiento/fisiología , Biomarcadores/orina , Dinoprostona/metabolismo , Femenino , Humanos , Lactante , MasculinoRESUMEN
We studied in vitro the effects on platelet aggregation and vascular tone of a new nitrocompound (nitroxy-butyl-acetylsalicylate: NO-ASA). In order to elucidate any possible activity due to the release of nitric oxide or the inhibition of platelet cyclo-oxygenase we compared NO-ASA to acetylsalicylic acid. NO-ASA 1 mM inhibited arachidonic acid-induced platelet aggregation (basal 75.4 +/- 2.35%; NO-ASA 22 +/- 3.46%; M +/- SEM; P < 0.001; n = 6), but proved less active than acetylsalicylic acid (complete inhibition at 2 x 10(-5) M). NO-ASA also significantly reduced thrombin-induced (0.04-0.08 U/ml) platelet aggregation in acetylsalicylic acid-treated platelets (basal 70.5 +/- 1.7%; NO-ASA 35.4 +/- 2.2%; P < 0.001; n = 10; IC50 7 x 10(-5) M). Methylene blue reduced the effects of NO-ASA on thrombin-induced (NO-ASA 46.7 +/- 5.25%; NO-ASA+MB 59.1 +/- 4.3%; P < 0.01; n = 8), but not arachidonic acid-induced platelet aggregation. The inhibitory effects of NO-ASA on platelet aggregation were partially removed by oxyhaemoglobin. Platelet thromboxane A2 production (TXB2 concentration in the supernatant of the aggregate 35.38 +/- 7.81 ng/ml; n = 8), was totally abolished by acetylsalicylic acid (0.17 +/- 0.04 ng/ml; P < 0.001; n = 8) and reduced by NO-ASA (8.3 +/- 4.05 ng/ml; P < 0.01; n = 8). In vitro studies on isolated rat aortic rings showed NO-ASA 10(-3) M, but not ASA up to 10(-3) M, induce a dose dependent vasorelaxation (100% of epinephrine-induced contraction) both in intact and endothelium denuded arteries (IC50 5 x 10(-5) M). Addition of methylene blue reversed this relaxation. In conclusion these data demonstrate that NO-ASA acts through a double mechanism: a) by inhibiting cyclo-oxygenase and b) by releasing NO active on guanylyn cyclase both in platelets and in vascular smooth muscle cells.
Asunto(s)
Aspirina/análogos & derivados , Músculo Liso Vascular/fisiología , Inhibidores de Agregación Plaquetaria/farmacología , Agregación Plaquetaria/efectos de los fármacos , Vasodilatación/efectos de los fármacos , Adulto , Animales , Aorta Torácica , Ácido Araquidónico/antagonistas & inhibidores , Aspirina/farmacología , Femenino , Humanos , Músculo Liso Vascular/efectos de los fármacos , Músculo Liso Vascular/metabolismo , Ratas , Ratas Sprague-Dawley , Trombina/antagonistas & inhibidores , Tromboxano A2/biosíntesisRESUMEN
The effects of a new ASA-nitroderivative compound, NCX 4016 (ASA-NO2), on platelet TXA2 synthesis after single and repeated doses in the rat were investigated. Compared to ASA, cumulative doses of ASA-NO2 showed similar inhibitory effects on platelet TXA2 synthesis and significant increases in nitrite/nitrate plasma concentrations 1 h after the last drug administration: 24 h later nitrite/nitrate plasma levels returned to the control values, while serum TXA2 concentrations did not change. A time-course study after a single dose of ASA-NO2 showed a significant inhibition of platelet TXA2 production also 24 h after drug administration and a significant increase in nitrite/nitrate plasma levels until 10 h.
Asunto(s)
Aspirina/farmacología , Plaquetas/efectos de los fármacos , Tromboxano A2/metabolismo , Animales , Aspirina/análogos & derivados , Plaquetas/metabolismo , Relación Dosis-Respuesta a Droga , Femenino , Nitritos/sangre , Ratas , Ratas Sprague-Dawley , Tromboxano B2/sangreRESUMEN
The pharmacokinetics of a new ASA-nitroderivative compound, NCX 4016 (ASA-NO2), was evaluated using an HPLC method. After single equimolar doses of ASA (35 mg kg(-1)) or ASA-NO2 (65 mg kg(-1)), no detectable levels of these compounds have been observed in rat plasma samples. SA peak levels were obtained at 3 h and 6 h after ASA and ASA-NO2 administration respectively. The elimination rate constants of SA were similar after ASA and ASA-NO2, suggesting a similar elimination phase of this metabolite in rats. From these data it is evident that ASA-NO2 is slowly metabolized in ASA, which is rapidly converted to SA.
Asunto(s)
Aspirina/farmacocinética , Animales , Aspirina/administración & dosificación , Aspirina/sangre , Cromatografía Líquida de Alta Presión , Femenino , Ratas , Ratas Sprague-DawleyRESUMEN
The effects of 14-day physical exercise or iloprost treatment (0.5-2 ng/Kg/min) on endogenous nitric oxide production and neutrophil adhesion were evaluated in 20 patients with peripheral arterial occlusive disease (Fontaine Stage II). Peripheral venous blood samples and 4-h urine samples were collected before, immediately after 14 days of therapy and 7-10 days after therapy in order to evaluate neutrophil adhesion, nitrite/nitrate and cGMP excretion rates. A longer pain free walking distance was observed after exercise, compared to iloprost (>500 m in 3/10 subjects). Urinary nitrite/nitrate, as well as cGMP concentrations, significantly increased after exercise. Nitrite/nitrate excretion rate inversely correlated to neutrophil adhesion. No variations were observed in these parameters in iloprost treated patients. The improvement in claudication and the transient increase in urinary nitrite/nitrate suggest a possible nitric oxide-dependent mechanism for the clinical efficacy of physical exercise. The results from the present and previous observations indicate that, besides pharmacological treatments, a regular aerobic exercise improves peripheral arterial occlusive disease.
Asunto(s)
Arteriopatías Oclusivas/metabolismo , Arteriopatías Oclusivas/fisiopatología , Terapia por Ejercicio , Óxido Nítrico/biosíntesis , Enfermedades Vasculares Periféricas/metabolismo , Enfermedades Vasculares Periféricas/fisiopatología , Anciano , Arteriopatías Oclusivas/terapia , Adhesión Celular/efectos de los fármacos , Humanos , Iloprost/uso terapéutico , Infusiones Intravenosas , Persona de Mediana Edad , Activación Neutrófila/efectos de los fármacos , Neutrófilos/efectos de los fármacos , Nitratos/orina , Óxido Nítrico/metabolismo , Nitritos/orina , Enfermedades Vasculares Periféricas/terapia , Vasodilatadores/uso terapéuticoRESUMEN
Previous studies have shown a role for nitric oxide (NO) as a cytotoxic effector. In the present work, two chemically different NO-donors such as glyceryl trinitrate (GTN) and S-nitroso-N-acetylpenicillamine (SNAP) were evaluated for both NO release and cytostatic/cytotoxic properties. Nitrite accumulation in the supernatant of MCF-7 and U251 cell lines indicated a greater and quickly release of NO derived from SNAP. A time-course of hemoglobin absorption spectral changes showed a greater release of NO derived from GTN in presence of cells compared to the values observed in the media, confirming that the release of NO by GTN can be enzymatic and non-enzymatic. On the contrary, SNAP generated NO without contribution of cellular components and saturated oxyhemoglobin quickly, within 2 hours. Both NO-donors inhibited thymidine incorporation in a similar manner and dose-dependently in U251 cells, but not in MCF-7 cells, where SNAP at the highest tested dose of 1000 microM induced only a 33% cytostatic effect. About trypan blue exclusion test, after 24 h GTN and SNAP, releasing similar amounts of NO, showed comparable cytotoxic effects on U251 cells (50% dead cells), but not on MCF-7 cells, where GTN resulted more cytotoxic. From our data, the "in vitro" antitumoral activity of NO-donors seems to be related to the type of tumor cell lines, to the amount and duration of NO release.
Asunto(s)
Supervivencia Celular/efectos de los fármacos , Inhibidores Enzimáticos/toxicidad , Donantes de Óxido Nítrico/toxicidad , Óxido Nítrico/metabolismo , Nitroglicerina/toxicidad , Penicilamina/análogos & derivados , Biotransformación , Neoplasias Encefálicas/patología , Neoplasias de la Mama/patología , Inhibidores Enzimáticos/farmacocinética , Femenino , Glioblastoma/patología , Humanos , Cinética , Donantes de Óxido Nítrico/farmacocinética , Nitroglicerina/farmacocinética , Penicilamina/farmacocinética , Penicilamina/toxicidad , S-Nitroso-N-Acetilpenicilamina , Células Tumorales CultivadasRESUMEN
An accurate and sensitive HPLC method has been developed for the determination of nitrofenac, a new, original diclofenac derivate showing a good tolerability and a wide anti-inflammatory profile, diclofenac, and its metabolites in plasma. This method has been applied to evaluate the pharmacokinetic parameters of the drugs, using a noncompartmental model, after the oral administration of 5 mg/kg nitrofenac to rats. Nitrofenac and the internal standard flufenamic acid were dissolved in acetonitrile, and diclofenac was dissolved in methanol. The drugs were eluted from a 5 microns LC-8 column with a mobile phase consisting of acetonitrile/water (50/50 v/v) adjusted to pH 3.3 with glacial acetic acid, at a flow rate of 2 mL/min with UV detection at 280 nm for diclofenac and 275 nm for nitrofenac. The detection limit for the drugs in plasma was 25 ng/mL. The peak concentration of nitrofenac was reached 7 h after drug administration, while with diclofenac we observed three peaks at 2, 5, and 10 h; the mean residence time and the elimination rate constant for nitrofenac were 6.18 +/- 0.09 h and 0.37 +/- 0.03 h-1 respectively, while those for diclofenac were 12.24 +/- 0.11 h and 0.11 +/- 0.04 h-1. Under our conditions, the metabolism of nitrofenac produced 23% diclofenac and other metabolites: the plasma concentrations and kinetic characteristics of diclofenac are enough to induce an anti-inflammatory activity, while the clinical importance of the other metabolites remains to be elucidated.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacocinética , Diclofenaco/análogos & derivados , Animales , Antiinflamatorios no Esteroideos/sangre , Cromatografía Líquida de Alta Presión , Diclofenaco/sangre , Diclofenaco/farmacocinética , Concentración de Iones de Hidrógeno , Indicadores y Reactivos , Masculino , Ratas , Ratas Sprague-Dawley , Espectrofotometría UltravioletaRESUMEN
In the present study the effects of exogenous and endogenous nitric oxide (NO) on intestinal bacteria and on the intestinal tissue integrity have been investigated in healthy rats and in rats receiving bacterial endotoxin (LPS). A segment of jejunum was taken in order to evaluate tissue damage and hematoxylin-eosin staining; microbiological studies were carried out collecting stool samples. Administration of LPS (5 mg kg-1 i.v.) induced a moderate jejunal damage, which was completely prevented by NG-nitro-L-arginine methyl ester (L-NAME), 5 mg kg-1 s.c.), thus suggesting a damage of endogenous NO on the intestinal mucosa; sodium nitroprusside (SNP, 10 mg kg-1 os) reduced significantly jejunal damage induced by LPS. Endogenous NO produced by the administration of LPS resulted to be cytotoxic for all examined aerobic and anaerobic bacteria, while exogenous NO, released from SNP, showed an inhibitory effect only on Entero. faecalis and E. coli growth. From our data, it seems reasonable to conclude that high local levels of NO are required in order to observe jejunal damage and cytotoxic effects on aerobic and anaerobic faecal flora.